Recently, Smoore International Holdings Limited (hereinafter referred to as "Smoore", stock code: 6969) released its financial update for the period ending on September 30, 2024. According to the financial report, in the third quarter of 2024, Smoore's revenue reached 32.861 billion RMB, representing a 16.5% growth compared to the previous quarter and a 14.1% growth compared to the same period last year. The company's net profit after tax was 3.789 billion RMB, an increase of 10.2% compared to the previous quarter but a decrease of 22.5% year-on-year.
In the third quarter of 2024, Smoore's revenue reached 3.286 billion yuan, an increase of 16.5% compared to the previous quarter and 14.1% compared to the same period last year. This growth is primarily attributed to an increase in revenue from proprietary brand products and closed-loop products in the enterprise customer business. As of September 30, 2024, the company's total revenue was 8.3234 billion yuan, a year-on-year increase of 4.0%.
In the third quarter of 2024, Smoore Company's net profit after tax was 3.789 billion RMB, showing a quarter-on-quarter increase of 10.2% from 3.437 billion RMB in the second quarter. However, it decreased by 22.5% compared to 4.887 billion RMB in the same period last year. In the first nine months of 2024, the total net profit after tax was 10.621 billion RMB, a year-on-year decrease of 11.9% from 12.06 billion RMB in the same period in 2023. This decrease is mainly attributed to a significant increase in the provision for income tax expenses compared to the same period last year.
Smoore stated that the company will continue to increase investment in product development for HNB products and vaporized medical products projects.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
